

**A. ORIGIN OF THE REPORT**

A1		<b>Name of contracting Party:</b> Brazil
A3k		<b>Web page</b> <a href="http://www.inca.gov.br/observatoriotabaco">www.inca.gov.br/observatoriotabaco</a>
1		<b>Period of reporting:</b>
	1	<b>Start date</b> January 2019
	1	<b>End date</b> January 2023

**B1. TOBACCO CONSUMPTION**

B1		<b>Prevalence of tobacco use</b>
B11		<b>Smoking prevalence in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered, e.g. 15 years old and over, 18-64 years; see B112)</b>
1_SQ001		<b>Current smokers</b>
	1_SQ001	<b>MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 15.9
	1_SQ002	<b>MALE [Average number of the most-consumed smoking tobacco product used per day]</b> Not available
	2_SQ001	<b>FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 9.6
	2_SQ002	<b>FEMALE [Average number of the most-consumed smoking tobacco product used per day]</b> Not available
	3_SQ001	<b>TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 12.6
	3_SQ002	<b>TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]</b> Not available
1_SQ001		<b>Daily smokers</b>
	1_SQ001	<b>MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 14.3
	1_SQ002	<b>MALE [Average number of the most-consumed smoking tobacco product used per day]</b> 13.2
	2_SQ001	<b>FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 8.8
	2_SQ002	<b>FEMALE [Average number of the most-consumed smoking tobacco product used per day]</b> 11.7
	3_SQ001	<b>TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 11.4

	3_SQ002	<b>TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]</b>  12.6
1_SQ001		<b>Occasional smokers</b>
	1_SQ001	<b>MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
	2_SQ001	<b>FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
	3_SQ001	<b>TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
1_SQ001		<b>Former smokers</b>
	1_SQ001	<b>MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  26.3
	2_SQ001	<b>FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  27.3
	3_SQ001	<b>TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  26.8
1_SQ001		<b>Never smokers</b>
	1_SQ001	<b>MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
	2_SQ001	<b>FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
	3_SQ001	<b>TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>  Not available
B111		<b>Please indicate the smoking tobacco products included in calculating prevalence for question B11:</b>  Manufactured cigarettes, hand-rolled or straw cigarettes, clove or bali cigarettes, bidis or Indian cigarettes, pipes, cigars or cigarillos and narghilé.
1_SQ001		<b>Please indicate the age range to which the data used to answer question B11 refer:</b>
	1_SQ001	<b>Age range [From]</b>

		18
	1_SQ002	<b>Age range [To]</b> 100
B113A		<b>Please indicate the year of the data used to answer question B11:</b> 2019
B113B		<b>Please indicate the source of the data used to answer question B11:</b> Global Adult Tobacco Survey, which was included as part of the National Health Survey (PNS) conducted in 2019. Brazilian Geography and Statistics Institute (IBGE). Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal : Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde] Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal: Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde]. Available at: <a href="https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764">https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764</a>
SQ001		<b>Please provide the definitions of “current smoker”, “daily smoker”, “occasional smoker”, “former smoker” and “never smoker” used in this report.</b>
	SQ001	<b>Current smoker</b> Person who regularly uses at least one of the smoked tobacco products, regardless of the time he/she has been smoking for. It comprehends daily and occasional smokers
	SQ002	<b>Daily smoker</b> Person who uses at least one of the smoked tobacco products daily, regardless of the time he/she has been smoking. Short periods of time in which a person did not smoke tobacco due to special situations, such as illness, travels etc., but not due to the decision to definitely quit smoking, are not considered.
	SQ003	<b>Occasional smoker</b> Person who uses at least one of the smoked tobacco products, but not daily, regardless of the time he/she has been smoking for
	SQ004	<b>Former smoker</b> Person who, in the past, made use of at least one smoked tobacco products occasionally for a period of three months or more, or daily for a period of one month or more
	SQ005	<b>Never smoker</b> Person who never smoked tobacco, but may have tried it; or a person who smoked daily for less than a month; or occasionally for less than three months.
B115		<b>Please provide a brief explanation of the trend in smoking prevalence in the adult population in the past two years or since submission of your last report.</b> For both genders and for all categories of selected sociodemographic variables, unadjusted cigarette smoking prevalence rates decreased over time (between 2013 and 2019).
B12a_B12x1		<b>Smoking prevalence in the adult population (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)</b>
	B12a_B12x1	<b>MALES - current smokers1 [Range - start age]</b> Not available
	B12a_B12x3	<b>MALES - current smokers1 [Range - end age]</b>

		Not available
	B12a_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> Not available
	B12b_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12b_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12b_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12c_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12c_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12c_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12d_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12d_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12d_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12e_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12e_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12e_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12ee_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12ee_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12ee_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12eee_B12x 1	<b>MALES - current smokers1 [Range - start age]</b>

	B12eee_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12eee_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12eeee_B12x1	<b>MALES - current smokers1 [Range - start age]</b>
	B12eeee_B12x3	<b>MALES - current smokers1 [Range - end age]</b>
	B12eeee_B12x2	<b>MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12f_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b> Not available
	B12f_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b> Not available
	B12f_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> Not available
	B12g_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12g_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12g_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12h_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12h_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12h_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12i_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12i_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12i_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12j_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>

	B12j_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12j_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12jj_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12jj_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12jj_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12jjj_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12jjj_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12jjj_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12jjjj_B12x1	<b>FEMALES - current smokers1 [Range - start age]</b>
	B12jjjj_B12x3	<b>FEMALES - current smokers1 [Range - end age]</b>
	B12jjjj_B12x2	<b>FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12k_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b> 18
	B12k_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b> 24
	B12k_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 10.6
	B12l_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b> 25
	B12l_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b> 39
	B12l_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 11.8

	B12m_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b> 40
	B12m_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b> 59
	B12m_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 14.7
	B12n_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b> 60
	B12n_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b> 100
	B12n_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b> 11.4
	B12o_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b>
	B12o_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b>
	B12o_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12oo_B12x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b>
	B12oo_B12x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b>
	B12oo_B12x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12ooo_B12x 1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b>
	B12ooo_B12x 3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b>
	B12ooo_B12x 2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	B12oooo_B12 x1	<b>TOTAL (males and females) - current smokers1 [Range - start age]</b>
	B12oooo_B12 x3	<b>TOTAL (males and females) - current smokers1 [Range - end age]</b>
	B12oooo_B12 x2	<b>TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>



B121		<p><b>Please indicate the smoking tobacco products included in calculating prevalence for question B12:</b></p> <p>Manufactured cigarettes, hand-rolled or straw cigarettes, clove or bali cigarettes, bidis or Indian cigarettes, pipes, cigars or cigarillos, narghilé.</p>
B122A		<p><b>Please indicate the year of the data used to answer question B12:</b></p> <p>2019</p>
B122B		<p><b>Please indicate the source of the data used to answer question B12:</b></p> <p>Global Adult Tobacco Survey, which was included as part of the National Health Survey (PNS) conducted in 2019. Brazilian Geography and Statistics Institute (IBGE). Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal : Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal: Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde]. Available at: <a href="https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764">https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764</a></p>
B123		<p><b>Please provide a brief explanation of the trend in current smoking prevalence by age group in the past two years or since submission of your last report, if data are available.</b></p>
B13		<p><b>Prevalence of smokeless tobacco use in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered in B132, e.g. 15 years old and over, 18-64 years; see B132)</b></p>
1_B13x1		<p><b>Males</b></p>
	1_B13x1	<p><b>Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>
	2_B13x1	<p><b>Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>
	3_B13x1	<p><b>Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>
	4_B13x1	<p><b>Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>
	5_B13x1	<p><b>Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>
1_B13x1		<p><b>Females</b></p>
	1_B13x1	<p><b>Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b></p> <p>Not available</p>

	2_B13x1	<b>Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	3_B13x1	<b>Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	4_B13x1	<b>Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	5_B13x1	<b>Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
1_B13x1		<b>TOTAL (males and females)</b>
	1_B13x1	<b>Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	2_B13x1	<b>Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	3_B13x1	<b>Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	4_B13x1	<b>Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	5_B13x1	<b>Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
B131		<b>Please indicate the smokeless tobacco products included in calculating prevalence for question B13:</b> Snuff (rapé), chewing tobacco and any other tobacco product which does not produce smoke.
1_SQ001		<b>Please indicate the age range to which the data used to answer question B13 refer:</b>
	1_SQ001	<b>Age range [From]</b>
	1_SQ002	<b>Age range [To]</b>
B133A		<b>Please indicate the year of the data used to answer question B13:</b> 2019
B133B		<b>Please indicate the source of the data used to answer question B13:</b>

SQ001		<b>Please provide the definitions of “current user”, “daily user”, “occasional user”, “former user” and “never user” (of smokeless tobacco products) used in this report in the space below.</b>
	SQ001	<b>Current user</b> Person who regularly uses at least one of the smokeless tobacco products, regardless of the time he/she has been using. It comprehends daily and occasional smokers
	SQ002	<b>Daily user</b> Person who uses at least one of the smokeless tobacco products daily, regardless of the time he/she has been using. Short periods of time in which a person did not smoke tobacco due to special situations, such as illness, travels etc., but not due to the decision to definitely quit using, are not considered.
	SQ003	<b>Occasional user</b> Person who uses at least one of the smokeless tobacco products, but not daily, regardless of the time he/she has been using
	SQ004	<b>Former user</b> Not available
	SQ005	<b>Never user</b> Not available
B135		<b>Please provide a brief explanation of the trend in smokeless tobacco use in the adult population in the past two years or since submission of your last report.</b>
B12a_B12x1		<b>Prevalence of smokeless tobacco use in the adult population (current users) by age group (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)</b>
	B12a_B12x1	<b>MALES - current users2 [Age group (adults)]</b> Not available
	B12a_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	B12b_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
	B12b_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12c_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
	B12c_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12d_B12x1	<b>MALES - current users2 [Age group (adults)]</b>

B12d_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12e_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
B12e_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12ee_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
B12ee_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12eee_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
B12eee_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12eeee_B12x1	<b>MALES - current users2 [Age group (adults)]</b>
B12eeee_B12x2	<b>MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12f_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
B12f_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12g_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b> Not available
B12g_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
B12h_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
B12h_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B12i_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
B12i_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>

	B12j_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
	B12j_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12jj_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
	B12jj_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12jjj_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
	B12jjj_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12jjjj_B12x1	<b>FEMALES - current users2 [Age group (adults)]</b>
	B12jjjj_B12x2	<b>FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12k_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b> Not available
	B12k_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b> Not available
	B12l_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12l_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12m_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12m_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12n_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12n_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12o_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>

	B12o_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12oo_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12oo_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12ooo_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12ooo_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
	B12oooo_B12x1	<b>TOTAL (males and females) - current users2 [Age group (adults)]</b>
	B12oooo_B12x2	<b>TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]</b>
B141		<b>Please indicate the smokeless tobacco products included in the answer to question B14:</b>  Snuff (rapé), chewing tobacco and any other tobacco product which does not produce smoke.
B142A		<b>Please indicate the year of the data used to answer question B14:</b>  2019
B142B		<b>Please indicate the source of the data used to answer question B14:</b>
B143		<b>Please provide a brief explanation of the trend in current use of smokeless tobacco by adult age groups in the past two years or since submission of your last report.</b>
B15a_B15x1		<b>Tobacco use by ethnic group(s) (please include all smoking or smokeless tobacco products in prevalence data)</b>
	B15a_B15x1	<b>Current users 3 [Ethnic group(s)]</b>  White
	B15a_B15x2	<b>Current users 3 [MALES - Prevalence (%)]</b>
	B15a_B15x3	<b>Current users 3 [FEMALES - Prevalence (%)]</b>
	B15a_B15x4	<b>Current users 3 [TOTAL (males and females) - Prevalence (%)]</b>  11.6
	B15b_B15x1	<b>Current users 3 [Ethnic group(s)]</b>  Black

	B15b_B15x2	<b>Current users 3 [MALES - Prevalence (%)]</b>
	B15b_B15x3	<b>Current users 3 [FEMALES - Prevalence (%)]</b>
	B15b_B15x4	<b>Current users 3 [TOTAL (males and females) - Prevalence (%)]</b> 13.5
	B15c_B15x1	<b>Current users 3 [Ethnic group(s)]</b> Brown
	B15c_B15x2	<b>Current users 3 [MALES - Prevalence (%)]</b>
	B15c_B15x3	<b>Current users 3 [FEMALES - Prevalence (%)]</b>
	B15c_B15x4	<b>Current users 3 [TOTAL (males and females) - Prevalence (%)]</b> 13.3
	B15d_B15x1	<b>Current users 3 [Ethnic group(s)]</b>
	B15d_B15x2	<b>Current users 3 [MALES - Prevalence (%)]</b>
	B15d_B15x3	<b>Current users 3 [FEMALES - Prevalence (%)]</b>
	B15d_B15x4	<b>Current users 3 [TOTAL (males and females) - Prevalence (%)]</b>
	B15e_B15x1	<b>Current users 3 [Ethnic group(s)]</b>
	B15e_B15x2	<b>Current users 3 [MALES - Prevalence (%)]</b>
	B15e_B15x3	<b>Current users 3 [FEMALES - Prevalence (%)]</b>
	B15e_B15x4	<b>Current users 3 [TOTAL (males and females) - Prevalence (%)]</b>
B151		<b>Please indicate the tobacco products included in the answer to question B15:</b> Manufactured cigarettes, hand-rolled or straw cigarettes, clove or Bali cigarettes, bidis or Indian cigarettes, pipes, cigars or cigarillos, narghilé, snuff (rapé), chewing tobacco and any other tobacco product which does not produce smoke.
1_SQ001		<b>Please indicate the age range to which the data used to answer question B15 refer:</b>
	1_SQ001	<b>Age range [From]</b> 18
	1_SQ002	<b>Age range [To]</b>

		100
B153A		<b>Please indicate the year of the data used to answer question B15:</b> 2019
B153B		<b>Please indicate the source of the data used to answer question B15:</b> Global Adult Tobacco Survey, which was included as part of the National Health Survey (PNS) conducted in 2019. Brazilian Geography and Statistics Institute (IBGE). Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal : Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde] Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal: Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde]. Available at: <a href="https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764">https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764</a>
B16a_B16x1		<b>Tobacco use by young persons (please include all smoking or smokeless tobacco products in prevalence data)</b>
	B16a_B16x1	<b>BOYS - Current users 4 [Age range]</b> 13-17
	B16a_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 7.1
	B16a_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16a_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16b_B16x1	<b>BOYS - Current users 4 [Age range]</b> 13-15
	B16b_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 4.5
	B16b_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16b_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16c_B16x1	<b>BOYS - Current users 4 [Age range]</b> 16-17
	B16c_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 11.9
	B16c_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16c_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16d_B16x1	<b>BOYS - Current users 4 [Age range]</b>



B16d_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16d_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16d_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16e_B16x1	<b>BOYS - Current users 4 [Age range]</b>
B16e_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16e_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16e_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16ee_B16x1	<b>BOYS - Current users 4 [Age range]</b>
B16ee_B16x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16ee_B16x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16ee_B16x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16eee_B16x 1	<b>BOYS - Current users 4 [Age range]</b>
B16eee_B16x 2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16eee_B16x 3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16eee_B16x 4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16eeee_B16 x1	<b>BOYS - Current users 4 [Age range]</b>
B16eeee_B16 x2	<b>BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16eeee_B16 x3	<b>BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16eeee_B16 x4	<b>BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>

B16f_B16x1	<b>GIRLS - Current users 4 [Age range]</b> 13-17
B16f_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 6.5
B16f_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16f_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16g_B16x1	<b>GIRLS - Current users 4 [Age range]</b> 13-15
B16g_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 5.6
B16g_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16g_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16h_B16x1	<b>GIRLS - Current users 4 [Age range]</b> 16-17
B16h_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 8.2
B16h_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16h_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16i_B16x1	<b>GIRLS - Current users 4 [Age range]</b>
B16i_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16i_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
B16i_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B16j_B16x1	<b>GIRLS - Current users 4 [Age range]</b>
B16j_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
B16j_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>

	B16j_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16jj_B16x1	<b>GIRLS - Current users 4 [Age range]</b>
	B16jj_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16jj_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16jj_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16jjj_B16x1	<b>GIRLS - Current users 4 [Age range]</b>
	B16jjj_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16jjj_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16jjj_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16jjjj_B16x1	<b>GIRLS - Current users 4 [Age range]</b>
	B16jjjj_B16x2	<b>GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16jjjj_B16x3	<b>GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16jjjj_B16x4	<b>GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16k_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b> 13-17
	B16k_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 6.8
	B16k_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16k_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b> 7.8
	B16l_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b> 13-15
	B16l_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>

		5.0
	B16l_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16l_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b> 6.7
	B16m_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b> 16-17
	B16m_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b> 10.0
	B16m_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16m_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b> 9.8
	B16n_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b>
	B16n_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16n_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16n_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16o_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b>
	B16o_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16o_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16o_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16oo_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b>
	B16oo_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]</b>
	B16oo_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>

		(%) ]
	B16oo_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16ooo_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b>
	B16ooo_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%) ]</b>
	B16ooo_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16ooo_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
	B16oooo_B16x1	<b>TOTAL (boys and girls) - Current users 4 [Age range]</b>
	B16oooo_B16x2	<b>TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%) ]</b>
	B16oooo_B16x3	<b>TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]</b>
	B16oooo_B16x4	<b>TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]</b>
B161		<b>Please indicate the tobacco products included in calculating prevalence for question B16:</b>
B162A		<b>Please indicate the year of the data used to answer question B16:</b> 2019
B162B		<b>Please indicate the source of the data used to answer question B16:</b> PeNSE/2019. Pesquisa Nacional de Saúde do Escolar: 2019. IBGE, Coordenação de População e Indicadores Sociais. Available at: <a href="https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101852">https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101852</a>
B163		<b>Please provide the definition of “current smoking/tobacco use” used to answer question B16 in the space below.</b> Individuals who smoked at least 1 manufactured cigarette in the last 30 days.
B164		<b>Please provide a brief explanation of the trend in tobacco use by young persons in the past two years or since submission of your last report.</b>
SQ001_SQ001		<b>Male</b>
	SQ001_SQ001	<b>Prevalence (%) (please include all smoking tobacco products in prevalence data) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>

	SQ001_SQ00 2	<b>Prevalence (%) (please include all smoking tobacco products in prevalence data) [Average number of the most-consumed smoking tobacco product used per day]</b>
	SQ002_SQ00 1	<b>Average number of the most-consumed smoking tobacco product used per day [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	SQ002_SQ00 2	<b>Average number of the most-consumed smoking tobacco product used per day [Average number of the most-consumed smoking tobacco product used per day]</b>
	SQ003_SQ00 1	<b>Occasional smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	SQ003_SQ00 2	<b>Occasional smokers [Average number of the most-consumed smoking tobacco product used per day]</b>
	SQ004_SQ00 1	<b>Former smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	SQ004_SQ00 2	<b>Former smokers [Average number of the most-consumed smoking tobacco product used per day]</b>
	SQ005_SQ00 1	<b>Never smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]</b>
	SQ005_SQ00 2	<b>Never smokers [Average number of the most-consumed smoking tobacco product used per day]</b>
1_1		<b>Use of novel and emerging tobacco and nicotine products</b>
	1_1	<b>Age range [Age range]</b>
	1_2	<b>Age range [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	1_3	<b>Age range [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	1_4	<b>Age range [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	1_5	<b>Age range [Other products - Prevalence (%)]</b>

	2_1	<b>Heated tobacco products (HTPs) - Prevalence (%) [Age range]</b>
	2_2	<b>Heated tobacco products (HTPs) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	2_3	<b>Heated tobacco products (HTPs) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	2_4	<b>Heated tobacco products (HTPs) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	2_5	<b>Heated tobacco products (HTPs) - Prevalence (%) [Other products - Prevalence (%)]</b>
	3_1	<b>Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Age range]</b>
	3_2	<b>Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	3_3	<b>Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	3_4	<b>Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	3_5	<b>Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Other products - Prevalence (%)]</b>
	4_1	<b>Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Age range]</b>
	4_2	<b>Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	4_3	<b>Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	4_4	<b>Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	4_5	<b>Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Other products - Prevalence (%)]</b>
	5_1	<b>Other products - Prevalence (%) [Age range]</b>

	5_2	<b>Other products - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	5_3	<b>Other products - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	5_4	<b>Other products - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	5_5	<b>Other products - Prevalence (%) [Other products - Prevalence (%)]</b>
	6_1	<b>YOUNG PERSONS - Total (boys and girls) [Age range]</b>
	6_2	<b>YOUNG PERSONS - Total (boys and girls) [Heated tobacco products (HTPs) - Prevalence (%)]</b>
	6_3	<b>YOUNG PERSONS - Total (boys and girls) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]</b>
	6_4	<b>YOUNG PERSONS - Total (boys and girls) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]</b>
	6_5	<b>YOUNG PERSONS - Total (boys and girls) [Other products - Prevalence (%)]</b>
B171		<b>Please indicate the year and source of the data used to answer question B17.</b>
B172		<b>Please provide a brief explanation of the trends - in adults and in young persons - in the use of novel and emerging tobacco and nicotine products in the past two years or since submission of your last report.</b>



**B2-B9. HEALTH, SOCIAL AND ECONOMIC INDICATORS**

B2		<b>Exposure to tobacco smoke</b>
B21		<b>Do you have any data on exposure to tobacco smoke in your population?</b> Yes
B22		<b>Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport).</b>  Individuals (nonsmokers) of 18 or more exposed to secondhand smoke at home: Men: 7.9 Women: 10.2 Total: 9.2 Individuals (nonsmokers) of 18 or more exposed to secondhand smoke at work indoors: Men: 10.4 Women: 6.7 Total: 8.4
B23A		<b>Please indicate the year of the data used to answer question B21:</b>  2019
B23B		<b>Please indicate the source of the data used to answer question B21:</b>  Global Adult Tobacco Survey, which was included as part of the National Health Survey (PNS) conducted in 2019. Brazilian Geography and Statistics Institute (IBGE). Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal : Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde] Pesquisa nacional de saúde : 2019 : percepção do estado de saúde, estilos de vida, doenças crônicas e saúde bucal: Brasil e grandes regiões / IBGE, Coordenação de Trabalho e Rendimento, [Ministério da Saúde]. Available at: <a href="https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764">https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&amp;id=2101764</a>
B3		<b>Tobacco-related mortality</b>
B31		<b>Do you have information on tobacco-related mortality in your population?</b> Yes
B32		<b>What is the estimated total number of deaths attributable to tobacco use in your population?</b>  443 deaths per day
B33		<b>If available, please provide any additional information on mortality attributable to tobacco use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.</b>  Annual deaths attributable to smoking in Brazil: - Chronic obstructive pulmonary disease: 37.686 - Heart diseases: 33.179 - Lung cancer: 24.443 - Other cancers: 25.683 - Passive smoking and other causes: 18.620 - Pneumonia: 12.201 - Stroke: 10.041
B34A		<b>Please indicate the year of the data used to answer question B32 and 33:</b>  2020
B34B		<b>Please indicate the source of the data used to answer questions B32 and B33:</b>  Palacios A, Bardach A, Casarini A, Rodríguez Cairoli F, Espinola N, Balan D, Perelli L, Augustovski F, Alcaraz A, Pichon-Riviere A. Estimación de carga de enfermedad, carga económica e impacto de los impuestos al tabaco en 8 países de América Latina. Reporte Metodológico. [Estimation of disease and economic burden, and impact of tobacco tax increases in 8 Latin American countries. Methodological report]. Documento Técnico IECS No. 60. Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina. Diciembre de 2020. Disponible en: <a href="http://www.iecs.org.ar/tabaco">www.iecs.org.ar/tabaco</a>
B4		<b>Tobacco-related costs</b>

B41		<p><b>Do you have information on the economic burden of tobacco use in your population, e.g. the overall cost of tobacco use imposed on your society?</b></p> <p>Yes</p>
B42		<p><b>Please provide details (e.g. direct (health care-related) and indirect costs and, if possible, the method used to estimate these costs).</b></p> <p>DIRECT COSTS IN THE HEALTH SYSTEM: - BRL 50.29 billion: expenditure per year on service of related diseases with tobacco consumption (Money earmarked for medical care in health centers and hospitals) - Diseases caused by smoking represent 7.8% of all annual expenses of the health country in health. INDIRECT COSTS TO SOCIETY: - BRL 74.86 billion/year: these are the costs of the people who get sick (and eventually die) and their families and close people who take on the tasks <a href="https://www.iecs.org.ar/wp-content/uploads/tabaco-brasil.pdf">https://www.iecs.org.ar/wp-content/uploads/tabaco-brasil.pdf</a> Model of burden of disease associated with smoking: This is a mathematical model with first-order Monte Carlo microsimulation using a probabilistic simulation of each individual to incorporate the natural history, direct and indirect costs, and loss of quality of life associated with the main tobacco-related diseases. The model has been validated in various countries, as shown by previous studies. The selected diseases were: ischemic and nonischemic cardiac diseases, COPD, pneumonia and influenza, stroke, and the following types of cancer: lung, mouth and pharynx, esophagus, stomach, pancreas, kidneys and renal pelvis, larynx, uterine cervix, and myeloid leukemia. The model's methodological development and coding of the diseases by the 10th revision of the International Classification of Diseases (ICD-10) have been presented in detail in previous studies. The model was programmed in Excel (<a href="https://products.office.com/">https://products.office.com/</a>) with macros in visual basic. <a href="https://www.iecs.org.ar/tabacismo-en-brasil/#tab-1-3">https://www.iecs.org.ar/tabacismo-en-brasil/#tab-1-3</a></p>
B43A		<p><b>Please indicate the year of the data used to answer question B42:</b></p> <p>2020</p>
B43B		<p><b>Please indicate the source of the data used to answer question B42:</b></p> <p>Palacios A, Bardach A, Casarini A, Rodríguez Cairoli F, Espinola N, Balan D, Perelli L, Augustovski F, Alcaraz A, Pichon-Riviere A. Estimación de carga de enfermedad, carga económica e impacto de los impuestos al tabaco en 8 países de América Latina. Reporte Metodológico. [Estimation of disease and economic burden, and impact of tobacco tax increases in 8 Latin American countries. Methodological report]. Documento Técnico IECS No. 60. Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina. Diciembre de 2020. Disponible en: <a href="http://www.iecs.org.ar/tabaco">www.iecs.org.ar/tabaco</a></p>
B5		<p><b>Supply of tobacco and tobacco products (with reference to Articles 6.2(b), 20.4(c), and 15.5)</b></p>
B51a_B51x1		<p><b>Licit supply of tobacco products</b></p>
	B51a_B51x1	<p><b>Smoking tobacco products [Product]</b></p> <p>Cigarette</p>
	B51a_B51x2	<p><b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b></p> <p>Million of packs</p>
	B51a_B51x3	<p><b>Smoking tobacco products [Domestic production]</b></p> <p>3.770,027</p>
	B51a_B51x4	<p><b>Smoking tobacco products [Retail sales]</b></p> <p>-</p>
	B51a_B51x5	<p><b>Smoking tobacco products [Exports]</b></p> <p>395,195</p>
	B51a_B51x6	<p><b>Smoking tobacco products [Imports]</b></p> <p>48,240</p>

	B51b_B51x1	<b>Smoking tobacco products [Product]</b>
	B51b_B51x2	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51b_B51x3	<b>Smoking tobacco products [Domestic production]</b>
	B51b_B51x4	<b>Smoking tobacco products [Retail sales]</b>
	B51b_B51x5	<b>Smoking tobacco products [Exports]</b>
	B51b_B51x6	<b>Smoking tobacco products [Imports]</b>
	B51c_B51x1	<b>Smoking tobacco products [Product]</b>
	B51c_B51x2	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51c_B51x3	<b>Smoking tobacco products [Domestic production]</b>
	B51c_B51x4	<b>Smoking tobacco products [Retail sales]</b>
	B51c_B51x5	<b>Smoking tobacco products [Exports]</b>
	B51c_B51x6	<b>Smoking tobacco products [Imports]</b>
	B51cc_B51x1	<b>Smoking tobacco products [Product]</b>
	B51cc_B51x2	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51cc_B51x3	<b>Smoking tobacco products [Domestic production]</b>
	B51cc_B51x4	<b>Smoking tobacco products [Retail sales]</b>
	B51cc_B51x5	<b>Smoking tobacco products [Exports]</b>
	B51cc_B51x6	<b>Smoking tobacco products [Imports]</b>
	B51ccc_B51x 1	<b>Smoking tobacco products [Product]</b>

B51ccc_B51x 2	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
B51ccc_B51x 3	<b>Smoking tobacco products [Domestic production]</b>
B51ccc_B51x 4	<b>Smoking tobacco products [Retail sales]</b>
B51ccc_B51x 5	<b>Smoking tobacco products [Exports]</b>
B51ccc_B51x 6	<b>Smoking tobacco products [Imports]</b>
B51cccc_B51 x1	<b>Smoking tobacco products [Product]</b>
B51cccc_B51 x2	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
B51cccc_B51 x3	<b>Smoking tobacco products [Domestic production]</b>
B51cccc_B51 x4	<b>Smoking tobacco products [Retail sales]</b>
B51cccc_B51 x5	<b>Smoking tobacco products [Exports]</b>
B51cccc_B51 x6	<b>Smoking tobacco products [Imports]</b>
B51d_B51x1	<b>Smokeless tobacco products [Product]</b>
B51d_B51x2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
B51d_B51x3	<b>Smokeless tobacco products [Domestic production]</b>
B51d_B51x4	<b>Smokeless tobacco products [Retail sales]</b>
B51d_B51x5	<b>Smokeless tobacco products [Exports]</b>
B51d_B51x6	<b>Smokeless tobacco products [Imports]</b>
B51e_B51x1	<b>Smokeless tobacco products [Product]</b>
B51e_B51x2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>

	B51e_B51x3	<b>Smokeless tobacco products [Domestic production]</b>
	B51e_B51x4	<b>Smokeless tobacco products [Retail sales]</b>
	B51e_B51x5	<b>Smokeless tobacco products [Exports]</b>
	B51e_B51x6	<b>Smokeless tobacco products [Imports]</b>
	B51f_B51x1	<b>Smokeless tobacco products [Product]</b>
	B51f_B51x2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51f_B51x3	<b>Smokeless tobacco products [Domestic production]</b>
	B51f_B51x4	<b>Smokeless tobacco products [Retail sales]</b>
	B51f_B51x5	<b>Smokeless tobacco products [Exports]</b>
	B51f_B51x6	<b>Smokeless tobacco products [Imports]</b>
	B51ff_B51x1	<b>Smokeless tobacco products [Product]</b>
	B51ff_B51x2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51ff_B51x3	<b>Smokeless tobacco products [Domestic production]</b>
	B51ff_B51x4	<b>Smokeless tobacco products [Retail sales]</b>
	B51ff_B51x5	<b>Smokeless tobacco products [Exports]</b>
	B51ff_B51x6	<b>Smokeless tobacco products [Imports]</b>
	B51fff_B51x1	<b>Smokeless tobacco products [Product]</b>
	B51fff_B51x2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51fff_B51x3	<b>Smokeless tobacco products [Domestic production]</b>

	B51fff_B51x4	<b>Smokeless tobacco products [Retail sales]</b>
	B51fff_B51x5	<b>Smokeless tobacco products [Exports]</b>
	B51fff_B51x6	<b>Smokeless tobacco products [Imports]</b>
	B51ffff_B51x 1	<b>Smokeless tobacco products [Product]</b>
	B51ffff_B51x 2	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51ffff_B51x 3	<b>Smokeless tobacco products [Domestic production]</b>
	B51ffff_B51x 4	<b>Smokeless tobacco products [Retail sales]</b>
	B51ffff_B51x 5	<b>Smokeless tobacco products [Exports]</b>
	B51ffff_B51x 6	<b>Smokeless tobacco products [Imports]</b>
	B51g_B51x1	<b>Other tobacco products [Product]</b>
	B51g_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51g_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51g_B51x4	<b>Other tobacco products [Retail sales]</b>
	B51g_B51x5	<b>Other tobacco products [Exports]</b>
	B51g_B51x6	<b>Other tobacco products [Imports]</b>
	B51h_B51x1	<b>Other tobacco products [Product]</b>
	B51h_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51h_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51h_B51x4	<b>Other tobacco products [Retail sales]</b>

	B51h_B51x5	<b>Other tobacco products [Exports]</b>
	B51h_B51x6	<b>Other tobacco products [Imports]</b>
	B51i_B51x1	<b>Other tobacco products [Product]</b>
	B51i_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51i_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51i_B51x4	<b>Other tobacco products [Retail sales]</b>
	B51i_B51x5	<b>Other tobacco products [Exports]</b>
	B51i_B51x6	<b>Other tobacco products [Imports]</b>
	B51ii_B51x1	<b>Other tobacco products [Product]</b>
	B51ii_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51ii_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51ii_B51x4	<b>Other tobacco products [Retail sales]</b>
	B51ii_B51x5	<b>Other tobacco products [Exports]</b>
	B51ii_B51x6	<b>Other tobacco products [Imports]</b>
	B51iii_B51x1	<b>Other tobacco products [Product]</b>
	B51iii_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51iii_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51iii_B51x4	<b>Other tobacco products [Retail sales]</b>
	B51iii_B51x5	<b>Other tobacco products [Exports]</b>

	B51iii_B51x6	<b>Other tobacco products [Imports]</b>
	B51iiii_B51x1	<b>Other tobacco products [Product]</b>
	B51iiii_B51x2	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B51iiii_B51x3	<b>Other tobacco products [Domestic production]</b>
	B51iiii_B51x4	<b>Other tobacco products [Retail sales]</b>
	B51iiii_B51x5	<b>Other tobacco products [Exports]</b>
	B51iiii_B51x6	<b>Other tobacco products [Imports]</b>
	B51j_B51x1	<b>Tobacco leaves [Product]</b>
	B51j_B51x2	<b>Tobacco leaves [Unit (e.g. pieces, tonnes)]</b>
	B51j_B51x3	<b>Tobacco leaves [Domestic production]</b>
	B51j_B51x4	<b>Tobacco leaves [Retail sales]</b>
	B51j_B51x5	<b>Tobacco leaves [Exports]</b>
	B51j_B51x6	<b>Tobacco leaves [Imports]</b>
B52		<b>Please provide information on the volumes of duty-free sales (e.g. product, unit, quantity), if available.</b>  This information is not available.
B53A		<b>Please indicate the year of the data used to answer question B51 and 52:</b>  2022
B53B		<b>Please indicate the source of the data used to answer questions B51 and B52:</b>  Secretariat of the Internal Revenue of Brazil.
B6		<b>Seizures of illicit tobacco products (with reference to Article 15.5)</b>
B61a_B61x1		<b>Seizures of illicit tobacco</b>
	B61a_B61x1	<b>Smoking tobacco products [Year]</b>



		2016
	B61a_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61a_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61a_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 205
	B61b_B61x1	<b>Smoking tobacco products [Year]</b> 2017
	B61b_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61b_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61b_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 225
	B61c_B61x1	<b>Smoking tobacco products [Year]</b> 2018
	B61c_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61c_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61c_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 276
	B61cc_B61x1	<b>Smoking tobacco products [Year]</b> 2019
	B61cc_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61cc_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61cc_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 235
	B61ccc_B61x 1	<b>Smoking tobacco products [Year]</b> 2020
	B61ccc_B61x 2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61ccc_B61x 3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61ccc_B61x 4	<b>Smoking tobacco products [Quantity seized ]</b>

		227
	B61cccc_B61x1	<b>Smoking tobacco products [Year]</b> 2021
	B61cccc_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61cccc_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61cccc_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 274
	B61cccc_B61x1	<b>Smoking tobacco products [Year]</b> 2022
	B61cccc_B61x2	<b>Smoking tobacco products [Product]</b> Cigarette
	B61cccc_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b> Million of packs
	B61cccc_B61x4	<b>Smoking tobacco products [Quantity seized ]</b> 162
	B61cccc_B61x1	<b>Smoking tobacco products [Year]</b>
	B61cccc_B61x2	<b>Smoking tobacco products [Product]</b>
	B61cccc_B61x3	<b>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61cccc_B61x4	<b>Smoking tobacco products [Quantity seized ]</b>
	B61d_B61x1	<b>Smokeless tobacco products [Year]</b>
	B61d_B61x2	<b>Smokeless tobacco products [Product]</b>
	B61d_B61x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61d_B61x4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61e_B61x1	<b>Smokeless tobacco products [Year]</b>
	B61e_B61x2	<b>Smokeless tobacco products [Product]</b>
	B61e_B61x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>

	B61e_B61x4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61f_B61x1	<b>Smokeless tobacco products [Year]</b>
	B61f_B61x2	<b>Smokeless tobacco products [Product]</b>
	B61f_B61x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61f_B61x4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61ff_B61x1	<b>Smokeless tobacco products [Year]</b>
	B61ff_B61x2	<b>Smokeless tobacco products [Product]</b>
	B61ff_B61x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61ff_B61x4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61fff_B61x1	<b>Smokeless tobacco products [Year]</b>
	B61fff_B61x2	<b>Smokeless tobacco products [Product]</b>
	B61fff_B61x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61fff_B61x4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61ffff_B61x 1	<b>Smokeless tobacco products [Year]</b>
	B61ffff_B61x 2	<b>Smokeless tobacco products [Product]</b>
	B61ffff_B61x 3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61ffff_B61x 4	<b>Smokeless tobacco products [Quantity seized ]</b>
	B61fffff_B61x 1	<b>Smokeless tobacco products [Year]</b>
	B61fffff_B61x 2	<b>Smokeless tobacco products [Product]</b>

B61ffff_B61x 3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
B61ffff_B61x 4	<b>Smokeless tobacco products [Quantity seized ]</b>
B61fffff_B61 x1	<b>Smokeless tobacco products [Year]</b>
B61fffff_B61 x2	<b>Smokeless tobacco products [Product]</b>
B61fffff_B61 x3	<b>Smokeless tobacco products [Unit (e.g. pieces, tonnes)]</b>
B61fffff_B61 x4	<b>Smokeless tobacco products [Quantity seized ]</b>
B61g_B61x1	<b>Other tobacco products [Year]</b>
B61g_B61x2	<b>Other tobacco products [Product]</b>
B61g_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
B61g_B61x4	<b>Other tobacco products [Quantity seized ]</b>
B61h_B61x1	<b>Other tobacco products [Year]</b>
B61h_B61x2	<b>Other tobacco products [Product]</b>
B61h_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
B61h_B61x4	<b>Other tobacco products [Quantity seized ]</b>
B61i_B61x1	<b>Other tobacco products [Year]</b>
B61i_B61x2	<b>Other tobacco products [Product]</b>
B61i_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
B61i_B61x4	<b>Other tobacco products [Quantity seized ]</b>
B61ii_B61x1	<b>Other tobacco products [Year]</b>

	B61ii_B61x2	<b>Other tobacco products [Product]</b>
	B61ii_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61ii_B61x4	<b>Other tobacco products [Quantity seized ]</b>
	B61iii_B61x1	<b>Other tobacco products [Year]</b>
	B61iii_B61x2	<b>Other tobacco products [Product]</b>
	B61iii_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61iii_B61x4	<b>Other tobacco products [Quantity seized ]</b>
	B61iiii_B61x1	<b>Other tobacco products [Year]</b>
	B61iiii_B61x2	<b>Other tobacco products [Product]</b>
	B61iiii_B61x3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61iiii_B61x4	<b>Other tobacco products [Quantity seized ]</b>
	B61iiii_B61x 1	<b>Other tobacco products [Year]</b>
	B61iiii_B61x 2	<b>Other tobacco products [Product]</b>
	B61iiii_B61x 3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61iiii_B61x 4	<b>Other tobacco products [Quantity seized ]</b>
	B61iiii_B61x 1	<b>Other tobacco products [Year]</b>
	B61iiii_B61x 2	<b>Other tobacco products [Product]</b>
	B61iiii_B61x 3	<b>Other tobacco products [Unit (e.g. pieces, tonnes)]</b>
	B61iiii_B61x 4	<b>Other tobacco products [Quantity seized ]</b>

B62		<p><b>Do you have any information on the percentage of illicit tobacco products on the national tobacco market?</b></p> <p>Yes</p>
B63		<p><b>What percentage of the national tobacco market do illicit tobacco products constitute? (%)</b></p> <p>31.4</p>
B64		<p><b>What is the trend over the past two years or since submission of your last report in the percentage of illicit tobacco products in relation to the national tobacco market?</b></p> <p>Not available - 2012 to 2013: there was an increase in the estimated proportion of illicit cigarette use (from 28.6% to 32.3%). - 2013 to 2014: a decrease from 32.3% to 28.8%. - 2014 to 2016: a sustained trend to increase from 28.8% to 42.8%. - 2016 to 2017: a decrease from 42.8% to 38.5% - 2017 to 2018: a decrease from 38.5% to 31.4%</p>
B65		<p><b>Please provide any further information on illicit tobacco products.</b></p> <p><a href="https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/observatorio-da-politica-nacional-de-controle-do-tabaco/dados-e-numeros-do-tabagismo/magnitude-do-comercio-ilicito-de-cigarros-no-brasil">https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/observatorio-da-politica-nacional-de-controle-do-tabaco/dados-e-numeros-do-tabagismo/magnitude-do-comercio-ilicito-de-cigarros-no-brasil</a></p>
B66		<p><b>Please indicate the source of the data used to answer questions in section B6:</b></p> <p>Source: Szklo A, Iglesias RM, Carvalho de Souza M, Szklo M, Maria de Almeida L. Trends in Illicit Cigarette Use in Brazil Estimated From Legal Sales, 2012-2016. Am J Public Health. 2018 Feb;108(2):265-269.</p>
B7		<p><b>Tobacco-growing</b></p>
B71		<p><b>Is there any tobacco-growing in your jurisdiction?</b></p> <p>Yes</p>
B72		<p><b>Please provide information on the number of workers involved in tobacco-growing. If available, please provide this figure broken down by gender.</b></p> <p>According to data from the Association of Tobacco Growers of Brazil (AFUBRA), there are 128.448 tobacco-producing families in the southern region of Brazil, where tobacco production is concentrated in the country (data from 2021/2022).</p>
B73		<p><b>Please provide, if available, the share of the value of tobacco leaf production in the national gross domestic product.</b></p> <p>Not available.</p>
B74A		<p><b>Please indicate the year of the data used to answer questions in section B7:</b></p> <p>2022</p>
B74B		<p><b>Please indicate the source of the data used to answer questions in section B7:</b></p> <p>Association of Tobacco Growers of Brazil (AFUBRA) AND MDA/SAF/Dater</p>
B8		<p><b>Taxation of tobacco products (with reference to Articles 6.2(a) and 6.3)</b></p>
B81		<p><b>What proportion of the retail price of the most popular price category of tobacco product consists of taxes (e.g. sum of excise, sales and import duties (if applicable) and value added tax/goods and services tax (VAT/GST))?</b></p> <p>79.0000000000</p>
SQ001		<p><b>How are the excise taxes levied (what types of taxes are levied)?</b></p>

	SQ001	<b>Specific tax only</b> No
	SQ002	<b>Ad valorem tax only</b> No
	SQ003	<b>Combination of specific and ad valorem taxes</b> Yes
	SQ004	<b>More complex structure (please explain below)</b> No
B82a		<b>If a more complex structure of taxes (please explain):</b>
B83a_B83x1		<b>If available, please provide details on the rates of taxation for tobacco products at all levels of Government and be as specific as possible (specify the type of tax, e.g. VAT, sales, import duties)</b>
	B83a_B83x1	<b>Smoking tobacco products [Product]</b> Cigarette
	B83a_B83x2	<b>Smoking tobacco products [Type of tax]</b> Specific Federal Rate
	B83a_B83x3	<b>Smoking tobacco products [Rate or amount]</b> R\$ 1.50
	B83a_B83x4	<b>Smoking tobacco products [Base of tax5]</b> Retail Price
	B83b_B83x1	<b>Smoking tobacco products [Product]</b> Cigarette
	B83b_B83x2	<b>Smoking tobacco products [Type of tax]</b> Ad-valorem Federal
	B83b_B83x3	<b>Smoking tobacco products [Rate or amount]</b> 21% (IPI,PIS,Cofins)
	B83b_B83x4	<b>Smoking tobacco products [Base of tax5]</b> Retail Price
	B83c_B83x1	<b>Smoking tobacco products [Product]</b> Cigarette
	B83c_B83x2	<b>Smoking tobacco products [Type of tax]</b> Ad-valorem state
	B83c_B83x3	<b>Smoking tobacco products [Rate or amount]</b> 32%
	B83c_B83x4	<b>Smoking tobacco products [Base of tax5]</b> Retail Price
	B83cc_B83x1	<b>Smoking tobacco products [Product]</b>

	B83cc_B83x2	<b>Smoking tobacco products [Type of tax]</b>
	B83cc_B83x3	<b>Smoking tobacco products [Rate or amount]</b>
	B83cc_B83x4	<b>Smoking tobacco products [Base of tax5]</b>
	B83ccc_B83x 1	<b>Smoking tobacco products [Product]</b>
	B83ccc_B83x 2	<b>Smoking tobacco products [Type of tax]</b>
	B83ccc_B83x 3	<b>Smoking tobacco products [Rate or amount]</b>
	B83ccc_B83x 4	<b>Smoking tobacco products [Base of tax5]</b>
	B83cccc_B83 x1	<b>Smoking tobacco products [Product]</b>
	B83cccc_B83 x2	<b>Smoking tobacco products [Type of tax]</b>
	B83cccc_B83 x3	<b>Smoking tobacco products [Rate or amount]</b>
	B83cccc_B83 x4	<b>Smoking tobacco products [Base of tax5]</b>
	B83ccccc_B8 3x1	<b>Smoking tobacco products [Product]</b>
	B83ccccc_B8 3x2	<b>Smoking tobacco products [Type of tax]</b>
	B83ccccc_B8 3x3	<b>Smoking tobacco products [Rate or amount]</b>
	B83ccccc_B8 3x4	<b>Smoking tobacco products [Base of tax5]</b>
	B83cccccc_B 83x1	<b>Smoking tobacco products [Product]</b>
	B83cccccc_B 83x2	<b>Smoking tobacco products [Type of tax]</b>
	B83cccccc_B 83x3	<b>Smoking tobacco products [Rate or amount]</b>
	B83cccccc_B 83x4	<b>Smoking tobacco products [Base of tax5]</b>



	B83d_B83x1	<b>Smokeless tobacco products [Product]</b>
	B83d_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
	B83d_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
	B83d_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
	B83e_B83x1	<b>Smokeless tobacco products [Product]</b>
	B83e_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
	B83e_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
	B83e_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
	B83f_B83x1	<b>Smokeless tobacco products [Product]</b>
	B83f_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
	B83f_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
	B83f_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
	B83ff_B83x1	<b>Smokeless tobacco products [Product]</b>
	B83ff_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
	B83ff_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
	B83ff_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
	B83fff_B83x1	<b>Smokeless tobacco products [Product]</b>
	B83fff_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
	B83fff_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>

B83fff_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
B83ffff_B83x1	<b>Smokeless tobacco products [Product]</b>
B83ffff_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
B83ffff_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
B83ffff_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
B83fffff_B83x1	<b>Smokeless tobacco products [Product]</b>
B83fffff_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
B83fffff_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
B83fffff_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
B83fffff_B83x1	<b>Smokeless tobacco products [Product]</b>
B83fffff_B83x2	<b>Smokeless tobacco products [Type of tax]</b>
B83fffff_B83x3	<b>Smokeless tobacco products [Rate or amount]</b>
B83fffff_B83x4	<b>Smokeless tobacco products [Base of tax5]</b>
B83g_B83x1	<b>Other tobacco products [Product]</b>
B83g_B83x2	<b>Other tobacco products [Type of tax]</b>
B83g_B83x3	<b>Other tobacco products [Rate or amount]</b>
B83g_B83x4	<b>Other tobacco products [Base of tax5]</b>
B83h_B83x1	<b>Other tobacco products [Product]</b>
B83h_B83x2	<b>Other tobacco products [Type of tax]</b>

	B83h_B83x3	<b>Other tobacco products [Rate or amount]</b>
	B83h_B83x4	<b>Other tobacco products [Base of tax5]</b>
	B83i_B83x1	<b>Other tobacco products [Product]</b>
	B83i_B83x2	<b>Other tobacco products [Type of tax]</b>
	B83i_B83x3	<b>Other tobacco products [Rate or amount]</b>
	B83i_B83x4	<b>Other tobacco products [Base of tax5]</b>
	B83ii_B83x1	<b>Other tobacco products [Product]</b>
	B83ii_B83x2	<b>Other tobacco products [Type of tax]</b>
	B83ii_B83x3	<b>Other tobacco products [Rate or amount]</b>
	B83ii_B83x4	<b>Other tobacco products [Base of tax5]</b>
	B83iii_B83x1	<b>Other tobacco products [Product]</b>
	B83iii_B83x2	<b>Other tobacco products [Type of tax]</b>
	B83iii_B83x3	<b>Other tobacco products [Rate or amount]</b>
	B83iii_B83x4	<b>Other tobacco products [Base of tax5]</b>
	B83iiii_B83x1	<b>Other tobacco products [Product]</b>
	B83iiii_B83x2	<b>Other tobacco products [Type of tax]</b>
	B83iiii_B83x3	<b>Other tobacco products [Rate or amount]</b>
	B83iiii_B83x4	<b>Other tobacco products [Base of tax5]</b>
	B83iiii_B83x 1	<b>Other tobacco products [Product]</b>

	B83iiii_B83x 2	<b>Other tobacco products [Type of tax]</b>
	B83iiii_B83x 3	<b>Other tobacco products [Rate or amount]</b>
	B83iiii_B83x 4	<b>Other tobacco products [Base of tax5]</b>
	B83iiii_B83x 1	<b>Other tobacco products [Product]</b>
	B83iiii_B83x 2	<b>Other tobacco products [Type of tax]</b>
	B83iiii_B83x 3	<b>Other tobacco products [Rate or amount]</b>
	B83iiii_B83x 4	<b>Other tobacco products [Base of tax5]</b>
B84		<p><b>Please briefly describe the trends in taxation for tobacco products in the past two years or since submission of your last report in your jurisdiction.</b></p> <p>The taxation rates are paralised since 2016. We expect to strenghten the taxation in the Tax Reform which is being discussed in the Parliament.</p>
B85		<p><b>Do you earmark any percentage of your taxation income for funding any national plan or strategy on tobacco control in your jurisdiction?</b></p> <p>No</p>
B86		<b>Please provide details in the space below.</b>
B87A		<p><b>Please indicate the year of the data used to answer questions B81 to B86:</b></p> <p>2022</p>
B87B		<p><b>Please indicate the source of the data used to answer questions B81 to B86:</b></p> <p>Secretariat of the Internal Revenue of Brazil</p>
B9		<b>Price of tobacco products (with reference to Articles 6.2(a))</b>
1_SQ001		<b>Domestic Please provide the retail prices of the three most widely sold brands of domestic tobacco products at the most widely used point of sale in your capital city.</b>
	1_SQ001	<p><b>Smoking tobacco products [Name of the most widely sold brand]</b></p> <p>Rothmans</p>
	1_SQ002	<p><b>Smoking tobacco products [Number of units or amount per package]</b></p> <p>20</p>
	1_SQ003	<p><b>Smoking tobacco products [Retail price]</b></p> <p>R\$ 6.00</p>
	1_SQ004	<b>Smoking tobacco products [Currency]</b>

	2_SQ001	<b>Smoking tobacco products [Name of the most widely sold brand]</b> Dunhill
	2_SQ002	<b>Smoking tobacco products [Number of units or amount per package]</b> 20
	2_SQ003	<b>Smoking tobacco products [Retail price]</b> R\$ 10.25
	2_SQ004	<b>Smoking tobacco products [Currency]</b>
	3_SQ001	<b>Smoking tobacco products [Name of the most widely sold brand]</b> Kent
	3_SQ002	<b>Smoking tobacco products [Number of units or amount per package]</b> 20
	3_SQ003	<b>Smoking tobacco products [Retail price]</b> R\$ 9.25
	3_SQ004	<b>Smoking tobacco products [Currency]</b>
	7_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	7_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	7_SQ003	<b>Smokeless tobacco products [Retail price]</b>
	7_SQ004	<b>Smokeless tobacco products [Currency]</b>
	8_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	8_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	8_SQ003	<b>Smokeless tobacco products [Retail price]</b>
	8_SQ004	<b>Smokeless tobacco products [Currency]</b>
	9_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	9_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	9_SQ003	<b>Smokeless tobacco products [Retail price]</b>

	9_SQ004	<b>Smokeless tobacco products [Currency]</b>
	13_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	13_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	13_SQ003	<b>Other tobacco products [Retail price]</b>
	13_SQ004	<b>Other tobacco products [Currency]</b>
	14_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	14_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	14_SQ003	<b>Other tobacco products [Retail price]</b>
	14_SQ004	<b>Other tobacco products [Currency]</b>
	15_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	15_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	15_SQ003	<b>Other tobacco products [Retail price]</b>
	15_SQ004	<b>Other tobacco products [Currency]</b>
1_SQ001		<b>Imported Please provide the retail prices of the three most widely sold brands of imported tobacco products at the most widely used point of sale in your capital city.</b>
	1_SQ001	<b>Smoking tobacco products [Name of the most widely sold brand]</b> Camel
	1_SQ002	<b>Smoking tobacco products [Number of units or amount per package]</b> 20
	1_SQ003	<b>Smoking tobacco products [Retail price]</b> R\$ 9.50
	1_SQ004	<b>Smoking tobacco products [Currency]</b>
	2_SQ001	<b>Smoking tobacco products [Name of the most widely sold brand]</b>

	2_SQ002	<b>Smoking tobacco products [Number of units or amount per package]</b>
	2_SQ003	<b>Smoking tobacco products [Retail price]</b>
	2_SQ004	<b>Smoking tobacco products [Currency]</b>
	3_SQ001	<b>Smoking tobacco products [Name of the most widely sold brand]</b>
	3_SQ002	<b>Smoking tobacco products [Number of units or amount per package]</b>
	3_SQ003	<b>Smoking tobacco products [Retail price]</b>
	3_SQ004	<b>Smoking tobacco products [Currency]</b>
	7_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	7_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	7_SQ003	<b>Smokeless tobacco products [Retail price]</b>
	7_SQ004	<b>Smokeless tobacco products [Currency]</b>
	8_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	8_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	8_SQ003	<b>Smokeless tobacco products [Retail price]</b>
	8_SQ004	<b>Smokeless tobacco products [Currency]</b>
	9_SQ001	<b>Smokeless tobacco products [Name of the most widely sold brand]</b>
	9_SQ002	<b>Smokeless tobacco products [Number of units or amount per package]</b>
	9_SQ003	<b>Smokeless tobacco products [Retail price]</b>
	9_SQ004	<b>Smokeless tobacco products [Currency]</b>

	13_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	13_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	13_SQ003	<b>Other tobacco products [Retail price]</b>
	13_SQ004	<b>Other tobacco products [Currency]</b>
	14_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	14_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	14_SQ003	<b>Other tobacco products [Retail price]</b>
	14_SQ004	<b>Other tobacco products [Currency]</b>
	15_SQ001	<b>Other tobacco products [Name of the most widely sold brand]</b>
	15_SQ002	<b>Other tobacco products [Number of units or amount per package]</b>
	15_SQ003	<b>Other tobacco products [Retail price]</b>
	15_SQ004	<b>Other tobacco products [Currency]</b>
B92A		<b>Please indicate the year of the data used to answer question B91:</b> 2022
B92B		<b>Please indicate the source of the data used to answer question B91:</b> Secretariat of the Internal Revenue of Brazil
B93		<b>Please briefly describe the trend in the prices of tobacco products in the past two years or since submission of your last report in your jurisdiction.</b>  The Decree 8.656 of January 29th 2016 determined a new increase in taxes on cigarettes from May 1st and further increase after December 1st 2016. It also raises the minimum price of the cigarette packages to R\$ 5.00 after May 1st 2016.



**C1. GENERAL OBLIGATIONS**

C1		<b>With reference to Article 5</b>
C111		<b>Have you developed and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention?</b>  Yes
C112		<b>Have you partially developed and implemented tobacco control strategies by including tobacco control in national health, public health or health promotion strategies, plans and programmes?</b>  N/A
C113		<b>Is any aspect of tobacco control that is referred to in the Convention included in any national strategy, plan or programme?</b>  N/A
C114a		<b>Have you established or reinforced and financed:</b>
	C114a	<b>a focal point for tobacco control?</b>  Yes
	C114b	<b>a tobacco control unit?</b>  Yes
	C114c	<b>a national coordinating mechanism for tobacco control?</b>  Yes
C115		<b>Please provide details (e.g. the nature of the national coordinating mechanism, the institution to which the focal point for tobacco control or the tobacco control unit belongs).</b>  The National Cancer Institute (INCA), body under the Ministry of Health, is responsible for implementing the National Tobacco Control Policy and works together with focal points at State Secretariats of Health in the 26 states and the Federal District. INCA is also in charge of coordinating the Executive Secretariat of the National Commission for the Implementation of the Framework Convention for Tobacco Control (CONICQ). This Commission was created by a Decree of the President of Brazil and is integrated by representatives of different Ministries of the government. It is chaired by the Minister of Health.
C116		<b>Please provide a brief description of the progress made in implementing Article 5.1 and 5.2 (General obligations) in the past two years or since submission of your last report.</b>  XXXX
C117		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>  XXX
C12		<b>Protection of public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b>
C121		<b>protecting public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry?</b>

		Yes
C122		<p><b>ensuring that the public has access, in accordance with Article 12(c), to a wide range of information on tobacco industry activities relevant to the objectives of the Convention, such as in a public repository?</b></p> <p>Yes</p>
C123		<p><b>If you answered “Yes” to any of the questions under C121 or C122, please provide details in the space below (specifically, please refer, if relevant, to whether your government or any of its departments 1) have raised awareness on tobacco industry tactics and the need to prevent interference by the tobacco industry with decision making; 2) have avoided entering into any partnerships or voluntary agreements with the tobacco industry; 3) have established any measures to limit interaction of public officials with the tobacco industry, including in the form of a code of conduct; 4) have not granted any incentives, privileges, benefits or preferential tax exemptions to the tobacco industry to establish or run their business; etc.).</b></p> <p>In order to report the strategies used by the tobacco industry through technical and document information, Tobacco Studies Center of the National Health School of Public Health (CETAB/ENSP/Fiocruz), the National Commission for FCTC Implementation (CONICQ/INCA), the International Union against Tuberculosis and Lung Disease (the Union) and the NGO Tobacco Control Alliance (ACT) launched the Observatory of Tobacco Industry Strategies on March 31, 2016. This observatory presents a new line of research focusing on knowledge and systematization of information about tobacco industry tactics. The digital platform follows the example of website Tobacco Tactics, hosted at the University of Bath, UK. The CONICQ's members must follow the ethical guidelines approved by the Ministry of Health, which determines rules and procedures in the interactions with tobacco industry and its related institutions.</p>
C124		<p><b>Please provide a brief description of the progress made in implementing Article 5.3 in the past two years or since submission of your last report.</b></p> <p>- The Court of Justice of the State of Rio de Janeiro welcomed the public civil action proposed by the Ministry Public of Rio de Janeiro against Rock World S.A., Vega Fina Tabacaria and Souza Cruz, for illegal advertising at Rock in Rio 2017 and 2019 festivals. - National Health Surveillance Agency (ANVISA) approves Regulatory Impact Analysis report on Electronic Smoking Devices, which includes all types of electronic cigarettes. The approved technical report indicates the need to maintain the ban on electronic devices for smoking, which includes all types of electronic cigarettes, and the adoption of additional measures to curb the illegal trade in these products, such as increasing inspection and carrying out educational campaigns.(2022)</p>
C125		<p><b>Have you utilized the “Guidelines for implementation of Article 5.3 of the WHO FCTC” when developing or implementing policies in this area?</b></p> <p>Yes</p>
C126		<p><b>Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. <a href="https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}&amp;lang=en</a></b></p> <p>XXX</p>
C127		<p><b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b></p> <p>The implementation of the FCTC/WHO in Brazil has major strategic axes, which guide compliance with Article 5.3 of the FCTC/WHO, aiming to protect its implementation from interference by the tobacco industry. With regard to this interference by the tobacco industry, which seeks to postpone the implementation of FCTC measures in Brazil, many of the arguments used by the sector are based on the fact that Brazil, an agro-exporting country, is the second largest tobacco producer and the largest exporter employing around 160,000 families in the tobacco leaf production chain. However, the National Diversification Program in areas cultivated with tobacco, which brought considerable advances to tobacco control in the country, has been discontinued in recent years. At COP 9, for example, we were surprised by the change in the delegation that would represent the country at the Conference on the eve of the event. The entire preparation of the instruction prepared to guide the positioning of the Brazilian delegation in the negotiation rounds had been previously coordinated by the CONICQ . It is a successful governmental committee instituted in 2003 by Presidential Decree with the aim of coordinating an Executive agenda for the</p>

	<p>internalization of Treaty measures. The Commission brings together different sectors of the federal government that share responsibilities in the national implementation of the intersectoral measures provided for in the Convention, being chaired by the Minister of Health and having the National Cancer Institute as its Executive Secretariat and Vice-Presidency. In the pre-COP period, its existence and legitimacy to act were strongly and publicly questioned by the tobacco industry. Despite attempts by the industry to obstruct the instruction regarding what Brazil's position, we were able to rely on Brazilian diplomacy: Ambassador Tovar da Silva Nunes, head of the Brazilian delegation at COP 9, supported the instruction previously agreed upon between the different bodies and secretariats that make up CONICQ, so that public health interests prevailed and going against the demands of representatives of the tobacco industry.</p>
--	---

**C2. MEASURES RELATING TO THE REDUCTION OF DEMAND FOR TOBACCO**

C2		<b>With reference to Articles 6-14</b>
C21		<b>Price and tax measures to reduce the demand for tobacco</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C211		<b>tax policies and, where appropriate, price policies on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption?</b> Yes
C212		<b>prohibiting or restricting, as appropriate, sales to international travellers of tax- and duty-free tobacco products?</b> No
C213		<b>prohibiting or restricting, as appropriate, imports by international travellers of tax- and duty-free tobacco products?</b> No
C214		<b>Please provide a brief description of the progress made in implementing Article 6 (Price and tax measures to reduce the demand for tobacco) in the past two years or since submission of your last report.</b>
C215		<b>Have you utilized the “Guidelines for implementation of Article 6 of the WHO FCTC” when developing or implementing policies in this area?</b> Yes
C216		<b>If you answered “Yes” to question C215 please provide details in the space below or refer to section H of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary . <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a></b> xxx
C217		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b> xxx
C22		<b>Protection from exposure to tobacco smoke</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C221		<b>- banning, completely or partially, tobacco smoking in indoor workplaces, public transport, indoor public places and, as appropriate, other public places?</b> Yes
1		<b>What is the type/nature of the measure providing for the ban?</b>
	1	<b>national law</b> Yes
	2	<b>subnational law(s)</b>

		Yes
	3	<b>administrative and executive orders</b> Yes
	4	<b>voluntary agreements</b> No
	5	<b>other measures (please specify in C223 below)</b>
C223		<b>Please provide a brief explanation of the type/nature and content of the measures providing for the ban.</b>
C224		<b>Do any of these measures provide for a mechanism/ infrastructure for enforcement?</b> Yes
C225		<b>Please provide details of this system.</b>  The enforcement of the smoke free law is in charge of the municipal health surveillance system, imposing penalties for noncompliance with the smoking ban, which can be monetary fines or suspension of the trade license.
1		<b>Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor workplaces:</b>
	1	<b>government buildings</b> Complete
	2	<b>health-care facilities</b> Complete
	3	<b>educational facilities<sup>6</sup></b> Complete
	4	<b>universities</b> Complete
	5	<b>private workplaces</b> Complete
	6	<b>other (please specify below)</b> None
C226aa		<b>Please provide a brief explanation of any "other" policies in the space below</b>
1		<b>Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Public transport:</b>
	1	<b>airplanes</b> Complete
	2	<b>trains</b>

		Complete
	3	<b>ferries</b> Complete
	4	<b>ground public transport (buses, trolleybuses, trams)</b> Complete
	5	<b>private vehicles</b> Complete
	6	<b>other (please specify below)</b> None
C226bb		<b>Please provide a brief explanation of any "other" policies in the space below</b>
1		<b>Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor public places:</b>
	1	<b>cultural facilities</b> Complete
	2	<b>shopping malls</b> Complete
	3	<b>pubs and bars</b> Complete
	4	<b>nightclubs</b> Complete
	5	<b>restaurants</b> Complete
	7	<b>other (please specify below)</b>
C226cc		<b>Please provide a brief explanation of any "other" policies in the space below</b>
C227		<b>Please provide a brief summary of complete and partial measures, with specific details of the partial measures that have been implemented:</b>
C227a		<b>Banning tobacco smoking in indoor workplaces</b>  - Since 1996 smoking is prohibited in the workplace. Law 9.294 / 96, regulated by Decree 2.018 / 96, prohibits the use of cigarettes, cigarillos, cigars, pipes or any other tobacco product, in a collective, private or public space.
C227b		<b>Banning tobacco smoking in public transport</b>  Since 2000 smoking was banned from public transport.
C227c		<b>Banning tobacco smoking in indoor public places</b>  Approved in 2011, but regulated in 2014, Law 12,546 prohibits smoking cigarillos, cigars, pipes, hookahs and other products in places of public or private use, such as halls and corridors of condominiums, restaurants and clubs - even if the environment is

		partially enclosed by a wall, partition, ceiling or awning. In case of non-compliance, commercial establishments may be fined and even lose their operating license. The Ministry of Health disseminated a national campaign in 2014 to strengthen the awareness on the national smoke free law. The campaign was disseminated in radio, magazines, buses and internet.
C228		<p><b>Please provide a brief description of the progress made in implementing Article 8 (Protection from exposure to tobacco smoke) in the past two years or since submission of your last report.</b></p> <p>Actually INCA and ANVISA are reinforcing the capacity building of local sanitary surveillance actors on this matter, including aspects of nicotine delivery systems, also prohibited. Until this moment, 550 professionals of 5 states were trained on legislative and enforcement aspects.</p>
C229		<p><b>Have you utilized the “Guidelines for implementation of Article 8 of the WHO FCTC” when developing or implementing policies in this area?</b></p> <p>Yes</p>
C2210		<p><b>If you answered “Yes” to question C229 please provide details in the space below or refer to section B of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b>  <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a></p> <p>xxx</p>
C2211		<p><b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b></p> <p>xxx</p>
C23		<p><b>Regulation of the contents of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b></p>
C231		<p><b>testing and measuring the contents of tobacco products?</b></p> <p>Yes</p>
C232		<p><b>testing and measuring the emissions of tobacco products?</b></p> <p>Yes</p>
C233		<p><b>regulating the contents of tobacco products?</b></p> <p>Yes</p>
C234		<p><b>regulating the emissions of tobacco products?</b></p> <p>Yes</p>
C235		<p><b>Please provide a brief description of the progress made in implementing Article 9 (Regulation of the contents of tobacco products) in the past two years or since submission of your last report.</b></p>
C236		<p><b>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</b></p> <p>Yes</p>
C237		<p><b>If you answered “Yes” to question C236 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b>  <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a></p> <p>xxx</p>

C238		<p><b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g., whether your country 1) has incorporated product regulation in the national tobacco control legislation; 2) has access to either governmental or independent - not owned or controlled by the tobacco industry - laboratories for testing contents and/or emissions of tobacco products; 3) has regulated ingredients, such as flavours (e.g. menthol); 4) has regulated product characteristics, such as design features (e.g., cigarette ventilation); etc.).</b></p> <p>In 2012 the National Agency of Sanitary Surveillance (Anvisa) edited the Collegiate Board Resolution (RDC 14/2012) prohibiting the use of additives that confers aroma and flavor to cigarettes. Anvisa is a Brazilian regulatory agency whose institutional purpose is to promote the population health protection by means of sanitary control of the production and consumption of products and services subjected to sanitary surveillance, including tobacco products. Also in 2012, the National Confederation of Industry (CNI) filed a Direct Action of Unconstitutionality (ADI 4874) questioning Anvisas competence to edit the RDC 14/2014. In the lawsuit, the CNI maintained that Anvisa exceeded the limits of its normative competence in the resolution edition. In addition CNI questioned the Law 9.782/1999 that creates the agency. The injunction requested by CNI was granted and the Anvisa Resolution (RDC 14/12) was suspended in 2013. The ADI 4874 judgment was resumed in November 2017 in the Brazilian Supreme Court (Supreme Federal Court - STF) and counted on the oral arguments of the parties and the amici curiae. These oral submissions received the honorable presentation of Mrs. Grace Maria Fernandes Mendonça, Minister of Federal Attorney General's Office (AGU). Speaking on behalf of the Presidency of the Republic and the National Congress, Mrs. Grace Fernandes argued that the discussion involved only the insertion of additives in the manufacture of cigarettes, not the prohibition of their sale. She presented numbers on the damage of smoking to public health and argued about the need of prohibiting the addition of flavors to the product due to its potential appeal to the young population, encouraging children and adolescents to initiate cigarette consumption. She argued that Anvisa acted within the regulatory limits assigned by the legislator, fulfilling its duty, in view of the recognized need to ban these additives, and in the spirit of agile response typical of regulatory agencies. She also observed the compliance with approval procedures with public hearings with more than 450 participants. The ADI judgment was concluded in February 2018. Most of the Supreme Court justices favored the constitutionality declaration of Law 9,782 that creates Anvisa. This fact means that the regulatory power of the agency was maintained, which is a great victory in favor of Public Health. However, regarding the specific aspect of the additives, there was a tie: the Supreme Court considered that the application of the Resolution would have no binding effect throughout the national jurisdiction, which means that the rule prohibiting the use of additives in cigarettes may be challenged in lower court environments. Articulated actions and the necessary measures to attack the injunctions granted in other instances are being taken. It is important to note that the Brazilian Federal Attorney Generals Office has played an important role throughout the process.</p>
C24		<p><b>Regulation of tobacco product disclosures Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b></p>
1		<p><b>requiring manufacturers or importers of tobacco products to disclose to Government authorities information about the:</b></p>
	1	<p><b>contents of tobacco products?</b></p> <p>Yes</p>
	2	<p><b>emissions of tobacco products?</b></p> <p>Yes</p>
1		<p><b>requiring public disclosure of information about the:</b></p>
	1	<p><b>contents of tobacco products?</b></p> <p>No</p>



	2	<b>emissions of tobacco products?</b> No
C243		<b>Please provide a brief description of the progress made in implementing Article 10 (Regulation of tobacco product disclosures) in the past two years or since submission of your last report.</b>
C244		<b>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</b> Yes
C245		<b>If you answered “Yes” to question C244 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary . <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a></b> xxx
C246		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether your country has incorporated tobacco product disclosures in the national tobacco control legislation; has regulated the public disclosure of toxic constituents and emissions of tobacco products, aiming to raise public awareness and advance tobacco control policy; etc.).</b> xxx
C25		<b>Packaging and labelling of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b>
C251		<b>requiring that packaging, individual cigarettes or other tobacco products do not carry advertising or promotion?</b> Yes
C252		<b>requiring that packaging and labelling do not promote a product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?</b> Yes
C253		<b>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products carry health warnings describing the harmful effects of tobacco use?</b> Yes
C254		<b>ensuring that the health warnings are approved by the competent national authority?</b> Yes
C255		<b>ensuring that the health warnings are rotated?</b> Yes
C256		<b>ensuring that the health warnings are clear, visible and legible?</b> Yes
C257		<b>Does your law mandate, as a minimum, a style, size and colour of font to render the warning clear, visible and legible?</b> Yes
C258		<b>ensuring that the health warnings occupy no less than 30% of the principal display areas?</b>

		Yes
C259		<b>ensuring that the health warnings occupy 50% or more of the principal display areas?</b> No
C2510		<b>ensuring that health warnings are in the form of, or include, pictures or pictograms?</b> Yes
C2511		<b>Does the Government own the copyright to these pictures and pictograms?</b> Yes
C2512		<b>Would you grant a non-exclusive and royalty-free licence for the use of health warnings developed in your jurisdiction with other Parties?</b> No
1		<b>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products contain information on relevant:</b>
	1	<b>constituents of tobacco products?</b> Yes
	2	<b>emissions of tobacco products?</b> No
C2514		<b>requiring that the warnings and other textual information appear on each unit packet and package and on any outside packaging and labelling in the principal language or languages of the country?</b> Yes
C2515		<b>Please provide a brief description of the progress made in implementing Article 11 (Packaging and labelling of tobacco products) in the past two years or since submission of your last report.</b>
C2516		<b>Have you utilized the “Guidelines for implementation of Article 11 of the WHO FCTC” when developing or implementing policies in this area?</b> Yes
C2517		<b>If you answered “Yes” to question C2516 please provide details in the space below or refer to section D of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a> xxx
C2518		<b>If you have any other relevant information pertaining to or not covered in this section, please provide details in the space below.</b> xxx
C26		<b>Education, communication, training and public awareness Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b>
C261		<b>educational and public awareness programmes? (Please refer to programmes implemented since submission of your two-year report.)</b>

		Yes
1		<b>To whom are these programmes targeted?</b>
	1	<b>adults or the general public</b> Yes
	2	<b>children and young people</b> Yes
	3	<b>men</b> Yes
	4	<b>women</b> Yes
	5	<b>pregnant women</b> No
	6	<b>ethnic groups</b> No
	7	<b>other</b> No
C2621		<b>Please specify</b>
1		<b>Do you reflect the following key differences among targeted population groups in educational and public awareness programmes?</b>
	1	<b>age</b> Yes
	2	<b>gender</b> Yes
	3	<b>educational background</b> Yes
	4	<b>cultural background</b> Yes
	5	<b>socioeconomic status</b> Yes
	6	<b>other</b> No
C2631		<b>Please specify</b>
1		<b>Do these educational and public awareness programmes cover:</b>

	1	<b>health risks of tobacco consumption?</b> Yes
	2	<b>health risks of exposure to tobacco smoke?</b> Yes
	3	<b>benefits of the cessation of tobacco use and tobacco-free lifestyles?</b> Yes
	4	<b>adverse economic consequences of tobacco production?</b> Yes
	5	<b>adverse economic consequences of tobacco consumption?</b> Yes
	6	<b>adverse environmental consequences of tobacco production?</b> Yes
	7	<b>adverse environmental consequences of tobacco consumption?</b> Yes
1		<b>awareness and participation of the following agencies and organizations in development and implementation of intersectoral programmes and strategies for tobacco control:</b>
	1	<b>public agencies?</b> Yes
	2	<b>nongovernmental organizations not affiliated with the tobacco industry?</b> Yes
	3	<b>private organizations?</b> No
	4	<b>other</b> No
C2651		<b>Please specify</b>
C266		<b>Are the elaboration, management and implementation of communication, education, training and public awareness programmes guided by research and do they undergo pre-testing, monitoring and evaluation?</b> No
1		<b>Are appropriate and special training or sensitization and awareness programmes on tobacco control addressed to:</b>
	1	<b>health workers?</b> Yes
	2	<b>community workers?</b> No
	3	<b>social workers?</b> No

	4	<b>media professionals?</b> No
	5	<b>educators?</b> Yes
	6	<b>decision-makers?</b> No
	7	<b>administrators?</b> No
	8	<b>other</b> No
C2671		<b>Please specify</b>
C268		<b>Please provide a brief description of the progress made in implementing Article 12 (Education, communication, training and public awareness) in the past two years or since submission of your last report.</b>
C269		<b>Have you utilized the “Guidelines for implementation of Article 12 of the WHO FCTC” when developing and implementing policies in this area?</b> No
C2610		<b>If you answered “Yes” to question C269 please provide details in the space below or refer to section E of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a>
C2611		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b> xxx
C27		<b>Tobacco advertising, promotion and sponsorship Have you adopted and implemented, where appropriate, any legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes:</b>
C271		<b>instituting a comprehensive ban on all tobacco advertising, promotion and sponsorship?</b> Yes
1		<b>Does your ban cover:</b>
	1	<b>display and visibility of tobacco products at points of sales?</b> No
	2	<b>the domestic Internet?</b> Yes
	3	<b>the global Internet?</b> No

	4	<b>brand stretching and/or brand sharing?</b> Yes
	5	<b>product placement as a means of advertising or promotion?</b> Yes
	6	<b>the depiction of tobacco or tobacco use in entertainment media products?</b> No
	7	<b>tobacco sponsorship of international events or activities and/or participants therein?</b> Yes
	8	<b>contributions from tobacco companies to any other entity for “socially responsible causes” and/or any other activities implemented under the umbrella of “corporate social responsibility” by the tobacco industry?</b> No
	9	<b>cross-border advertising, promotion and sponsorship originating from your territory?</b> No
	10	<b>the same forms of cross-border advertising, promotion and sponsorship entering your territory for which domestic regulation apply?</b> No
C273		<b>are you precluded by your constitution or constitutional principles from undertaking a comprehensive ban on tobacco advertising, promotion and sponsorship?</b> N/A
C274		<b>applying restrictions on all tobacco advertising, promotion and sponsorship?</b> N/A
C275		<b>applying restrictions on cross-border advertising, promotion and sponsorship originating from your territory with cross-border effects?</b> N/A
C276		<b>prohibiting those forms of tobacco advertising, promotion and sponsorship that promote a tobacco product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?</b> N/A
C277		<b>requiring that health or other appropriate warnings or messages accompany all tobacco advertising, promotion and sponsorship?</b> N/A
C278		<b>restricting the use of direct or indirect incentives that encourage the purchase of tobacco products by the public?</b> N/A
C279		<b>requiring the disclosure to relevant Government authorities of expenditures by the tobacco industry on advertising, promotion and sponsorship not yet prohibited?</b> N/A
1		<b>restricting tobacco advertising, promotion and sponsorship on:</b>

	1	<b>radio?</b> N/A
	2	<b>television?</b> N/A
	3	<b>print media?</b> N/A
	4	<b>the domestic Internet?</b> N/A
	5	<b>the global Internet?</b> N/A
	6	<b>other media?</b> N/A
C27101		<b>Please specify</b>
1		<b>restricting tobacco sponsorship of:</b>
	1	<b>international events and activities?</b> N/A
	2	<b>participants therein?</b> N/A
C2712		<b>cooperating with other Parties in the development of technologies and other means necessary to facilitate the elimination of cross-border advertising?</b> No
C2713		<b>imposing penalties for cross-border advertising equal to those applicable to domestic advertising, promotion and sponsorship originating from your territory in accordance with national law?</b> Yes
C2714		<b>Please provide a brief description of the progress made in implementing Article 13 (Tobacco advertising, promotion and sponsorship) in the past two years or since submission of your last report.</b>
C2715		<b>Have you utilized the “Guidelines for implementation of Article 13 of the WHO FCTC” when developing and implementing policies in this area?</b> Yes
C2716		<b>If you answered “Yes” to question C2715 please provide details in the space below or refer to section F of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a> xxx
C2717		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b> xxx
C28		<b>Demand reduction measures concerning tobacco dependence and cessation</b>

		<b>Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b>
C281		<b>developing and disseminating appropriate, comprehensive and integrated guidelines based on scientific evidence and best practices?</b> Yes
1		<b>programmes to promote cessation of tobacco use, including:</b>
	1	<b>media campaigns emphasizing the importance of quitting?</b> Yes
	2	<b>programmes specially designed for underage girls and young women?</b> No
	3	<b>programmes specially designed for women?</b> No
	4	<b>programmes specially designed for pregnant women?</b> No
	5	<b>telephone quitlines?</b> Yes
	6	<b>local events, such as activities related to World No Tobacco Day or National No Smoking Day, if appropriate?</b> Yes
	7	<b>other?</b> No
C2821		<b>Please specify</b>
1		<b>design and implementation of programmes aimed at promoting the cessation of tobacco use, in such locations as:</b>
	1	<b>educational institutions?</b> No
	2	<b>health-care facilities?</b> Yes
	3	<b>workplaces?</b> Yes
	4	<b>sporting environments?</b> No
	5	<b>other?</b> No
C2831		<b>Please specify</b>



1		<b>inclusion of diagnosis and treatment of tobacco dependence and counselling services for cessation of tobacco use in national programmes, plans and strategies for:</b>
	1	<b>tobacco control?</b> Yes
	2	<b>health?</b> No
	3	<b>education?</b> No
C285		<b>inclusion of programmes on the diagnosis and treatment of tobacco dependence in your health-care system?</b> Yes
1		<b>Which structures in your health-care system provide programmes for the diagnosis and treatment of tobacco dependence?</b>
	1	<b>primary health care</b> Yes
	2	<b>secondary and tertiary health care</b> Yes
	3	<b>specialist health-care systems (please specify below)</b> No
	4	<b>specialized centres for cessation counselling and treatment of tobacco dependence</b> No
	5	<b>rehabilitation centres</b> No
1		<b>Are the services provided in these settings covered by public funding or reimbursement schemes?</b>
	1	<b>primary health care</b> Fully
	2	<b>secondary and tertiary health care</b> Fully
	3	<b>specialist health-care systems (please specify below)</b>
	4	<b>specialized centres for cessation counselling and treatment of tobacco dependence</b>
	5	<b>rehabilitation centres</b>

	6	<b>other (please specify below)</b>
C287b		<b>Please provide other details in the space below.</b>
1		<b>Which health and other professionals are involved in programmes offering treatment for tobacco dependence and counselling services? Health professionals including:</b>
	1	<b>physicians</b> Yes
	2	<b>dentists</b> Yes
	3	<b>family doctors</b> Yes
	4	<b>practitioners of traditional medicine</b> Yes
	5	<b>other medical professionals (please specify below)</b> No
	6	<b>nurses</b> Yes
	7	<b>midwives</b> No
	8	<b>pharmacists</b> Yes
	9	<b>Community workers</b> No
	10	<b>Social workers</b> No
	11	<b>other (please specify)</b> No
1		<b>training on tobacco dependence treatment incorporated into the curricula of health professional training at pre- and post-qualification levels at the following schools:</b>
	1	<b>medical?</b> No
	2	<b>dental?</b> No
	3	<b>nursing?</b> No

	4	<b>pharmacy?</b> No
C2810		<b>facilitating accessibility and/or affordability of pharmaceutical products for the treatment of tobacco dependence?</b> Yes
C2811		<b>Where and how can these products be legally purchased in your country?</b> All products are offered by the government to state and municipalitie health departments and also are sold to the public in drugstores.
1		<b>Which pharmaceutical products are legally available for the treatment of tobacco dependence in your jurisdiction?</b>
	1	<b>nicotine replacement therapy</b> Yes
	2	<b>bupropion</b> Yes
	3	<b>varenicline</b> Yes
	4	<b>other (please specify)</b> No
1		<b>Are the costs of these products covered by public funding or reimbursement?</b>
	1	<b>nicotine replacement therapy</b> Fully
	2	<b>bupropion</b> Fully
	3	<b>varenicline</b>
	4	<b>other (please specify below)</b>
C2813b		<b>Please provide other details in the space below.</b>
C2814		<b>Please provide a brief description of the progress made in implementing Article 14 (Demand reduction measures concerning tobacco dependence and cessation) in the past two years or since submission of your last report.</b>
C2815		<b>Have you utilized the “Guidelines for implementation of Article 14 of the WHO FCTC” when developing and implementing policies in this area?</b> Yes
C2816		<b>Please provide details in the space below or refer to section G of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a> xxx

C2817		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>  xxx
-------	--	--

**C3. MEASURES RELATING TO THE REDUCTION OF THE SUPPLY OF TOBACCO**

C3		<b>With reference to Articles 15-17</b>
C31		<b>Illicit trade in tobacco products</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C311		<b>requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining the origin of the product?</b>  Yes
C312		<b>requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining whether the product is legally sold on the domestic market?</b>  Yes
C313		<b>requiring that unit packets and packages of tobacco products for retail and wholesale use that are sold on the domestic market carry the statement: “Sales only allowed in ...” or carry any other effective marking indicating the final destination of the product?</b>  Yes
C314		<b>developing a practical tracking and tracing regime that would further secure the distribution system and assist in the investigation of illicit trade?</b>  Yes
C315		<b>requiring that marking is presented in legible form and/or appears in the principal language or languages of the country?</b>  No
C316		<b>requiring the monitoring and collection of data on cross-border trade in tobacco products, including illicit trade?</b>  Yes
C317		<b>facilitating the exchange of this information among customs, tax and other authorities, as appropriate, and in accordance with national law and applicable bilateral and multilateral agreements?</b>  Yes
C318		<b>enacting or strengthening legislation, with appropriate penalties and remedies, against illicit trade in tobacco products, including counterfeit and contraband cigarettes?</b>  Yes
C319		<b>requiring that confiscated manufacturing equipment, counterfeit and contraband cigarettes and other tobacco products derived from illicit trade are destroyed, using environment-friendly methods where possible, or disposed of in accordance with national law?</b>  Yes
C3110		<b>adopting and implementing measures to monitor, document and control the storage and distribution of tobacco products held or moving under suspension of taxes or duties?</b>  Yes
C3111		<b>enabling the confiscation of proceeds derived from illicit trade in tobacco products?</b>

		No
C3112		<b>promoting cooperation between national agencies and relevant regional and international intergovernmental organizations in investigations, prosecutions and proceedings, with a view to eliminating illicit trade in tobacco products, with special emphasis on cooperation at regional and subregional levels?</b>  Yes
C3113		<b>licensing or other actions to control or regulate production and distribution in order to prevent illicit trade?</b>  Yes
C3114		<b>Please provide a brief description of the progress made in implementing Article 15 (Illicit trade in tobacco products) in the past two years or since submission of your last report.</b>
C3115		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>
C32		<b>Sales to and by minors Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</b>
C321		<b>prohibiting the sales of tobacco products to minors?</b>  Yes
C321a		<b>Please specify the legal age:</b>  18
C322		<b>requiring that all sellers of tobacco products place a clear and prominent indicator inside their point of sale about the prohibition of tobacco sales to minors?</b>  Yes
C323		<b>requiring that, in case of doubt, each seller of tobacco products requests that the purchaser provides appropriate evidence of having reached full legal age?</b>  Yes
C324		<b>banning the sale of tobacco products in any manner by which they are directly accessible, such as open store shelves?</b>  No
C325		<b>prohibiting the manufacture and sale of sweets, snacks, toys or any other objects in the form of tobacco products which appeal to minors?</b>  Yes
C326		<b>prohibiting the sale of tobacco products from vending machines?</b>  No
C327		<b>Do you ensure that tobacco vending machines are not accessible to minors and/or do not promote the sale of tobacco products to minors?</b>  No
1		<b>prohibiting and/or promoting the prohibition of the distribution of free tobacco products:</b>

	1	<b>to the public?</b> Yes
	2	<b>to minors?</b> Yes
C329		<b>prohibiting the sale of cigarettes individually or in small packets?</b> Yes
C3210		<b>providing for penalties against sellers and distributors in order to ensure compliance?</b> Yes
C3211		<b>prohibiting the sales of tobacco products by minors?</b> Yes
C3212		<b>Please provide a brief description of the progress made in implementing Article 16 (Sales to and by minors) in the past two years or since submission of your last report.</b>
C3213		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>  Proof of age at the time of purchasing tobacco products is not a common practice in Brazil. In the retail sector, it is not required to provide the buyers identity document, despite the prohibition in law. Thus, access to tobacco products is easier for young people.
C33		<b>Provision of support for economically viable alternative activities Have you adopted and implemented, where appropriate, measures or programmes on any of the following:</b>
1		<b>promoting economically viable and sustainable alternatives for:</b>
	1	<b>tobacco growers?</b> Yes
	2	<b>tobacco workers?</b> No
	3	<b>tobacco individual sellers?</b> No
C332		<b>Please provide a brief description of the progress made in implementing Article 17 (Provision of support for economically viable alternative activities) in the past two years or since submission of your last report.</b>
C333		<b>Have you utilized the “Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)” when developing and implementing policies in this area?</b> Yes
C334		<b>Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a>  xxx

C335	<p data-bbox="459 103 1412 168"><b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b></p> <p data-bbox="459 190 510 226">xxx</p>
------	--



**C4. OTHER MEASURES AND POLICIES**

C4		<b>With reference to Articles 18-21</b>
C41		<b>Protection of the environment and the health of persons</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		<b>implementing measures in respect of tobacco cultivation within your territory, which take into consideration:</b>
	1	<b>the protection of the environment?</b> Yes
	2	<b>the health of persons in relation to the environment?</b> Yes
1		<b>implementing measures in respect of tobacco manufacturing within your territory, which take into consideration:</b>
	1	<b>the protection of the environment?</b> Not applicable
	2	<b>the health of persons in relation to the environment?</b> Not applicable
C413		<b>Please provide a brief description of the progress made in implementing Article 18 (Protection of the environment and the health of persons) in the past two years or since submission of your last report.</b>  In 2020, the Ministry of Health included Green Leaf Disease of the Tobacco on the list of work-related diseases and in partnership with Center for Studies on Tobacco Use/National School of Public Health of the Foundation Oswaldo Cruz also started to invest in the development and implementation of a worker health surveillance protocol in tobacco farming for prevention, diagnosis, and appropriate treatment of this condition. At the time of publication of this Plan, the development of "Guidelines for Attention Integral to the Health of Tobacco Farming Workers".
C414		<b>Have you utilized the "Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)" when developing and implementing policies in this area?</b>  Yes
C415		<b>If you answered "Yes" to question C414 please provide details in the space below or refer to section I of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</b> <a href="https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en">https://extranet.who.int/dataformv3/862235?token={TOKEN}&amp;lang=en</a>  xxx
C416		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>  xxx
C42		<b>Liability</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

SQ001		<b>Does your tobacco control legislation contain measures regarding criminal liability for any violations of that tobacco control legislation?</b>
	SQ001	No
SQ001		<b>Do you have separate criminal liability provisions in relation to tobacco control (outside of the tobacco control legislation)?</b>
	SQ001	Yes
SQ001		<b>Do you have any civil liability measures that are specific to tobacco control?</b>
	SQ001	Yes
SQ001		<b>Do you have any general civil liability provisions that could apply to tobacco control?</b>
	SQ001	Yes
SQ001		<b>Do you have civil or criminal liability provisions that provide for compensation for adverse health effects and/or for reimbursement of medical, social or other relevant costs?</b>
	SQ001	No
SQ001		<b>Has any person in your jurisdiction launched any criminal and/or civil liability action, including compensation where appropriate, against any tobacco company in relation to any adverse health effect caused by tobacco use?</b>
	SQ001	Yes
SQ001		<b>Have you taken, as appropriate, any legislative, executive, administrative and/or other action against the tobacco industry for full or partial reimbursement of medical, social and other relevant costs related to tobacco use in your jurisdiction?</b>
	SQ001	Yes
C428		<b>Please provide a brief description of any progress made, as appropriate, in implementing Article 19 (Liability) in the past two years or since submission of your last report.</b>
C429		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</b>

		xxx
C43		<b>Research, surveillance and exchange of information</b> Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		<b>developing and/or promoting research that addresses:</b>
	1	<b>determinants of tobacco consumption?</b> Yes
	2	<b>consequences of tobacco consumption?</b> Yes
	3	<b>social and economic indicators related to tobacco consumption?</b> Yes
	4	<b>tobacco use among women, with special regard to pregnant women?</b> Yes
	5	<b>the determinants and consequences of exposure to tobacco smoke?</b> Yes
	6	<b>identification of effective programmes for the treatment of tobacco dependence?</b> Yes
	7	<b>identification of alternative livelihoods?</b> Yes
C4311		<b>Please specify</b>
C432		<b>training and support for all persons engaged in tobacco control activities, including research, implementation and evaluation?</b> Yes
1		<b>a national system for epidemiological surveillance of:</b>
	1	<b>patterns of tobacco consumption?</b> Yes
	2	<b>determinants of tobacco consumption?</b> Yes
	3	<b>consequences of tobacco consumption?</b> Yes
	4	<b>social, economic and health indicators related to tobacco consumption?</b> Yes
	5	<b>exposure to tobacco smoke?</b> Yes

C4331		<b>Please specify</b>
C434		<p><b>Please list all surveys, including the year of the survey, that you have undertaken in the past.</b></p> <p>1) The National Health and Nutrition Survey/1989. 2) The World Health Survey/2003. 3) The Global Adult Tobacco Survey/2008 and 2013 4) The Surveillance System for Risk and Protective Factors for Chronic Illnesses: Telephone Survey (VIGITEL)/2006-2016 5) Pinto M, Bardach A, Palacios A, Biz AN, Alcaraz A, Rodríguez B, Augustovski F, Pichon-Riviere A. Carga de doença atribuível ao uso do tabaco no Brasil e potencial impacto do aumento de preços por meio de impostos. (Disease burden attributable to tobacco use in Brazil and potential impact of price increases through taxes. Technical document IECS N° 21). Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina. May 2017. Available at: <a href="http://www.iecs.org.ar/tabaco">www.iecs.org.ar/tabaco</a> 6) Estimating the Size of Illicit Tobacco Consumption in Brazil: Findings from the Global Adult Tobacco Survey Roberto Magno Iglesias, André Salem Szklo, Mirian Carvalho de Souza, Liz Maria de Almeida <a href="http://tobaccocontrol.bmj.com/content/26/1/53">http://tobaccocontrol.bmj.com/content/26/1/53</a> 7) Trends in Illicit Cigarette Use in Brazil Estimated from Legal Sales: 2012-2016 André Szklo, Roberto Magno Iglesias, Mirian Carvalho de Souza, Moysés Szklo, Liz Maria de Almeida American Journal of Public Health 108, no. 2 (February 1, 2018): pp. 265-269. 8) Global Adult Tobacco Survey (Pesquisa Nacional de Saúde). 2019 9) Global Youth Survey (Pesquisa Nacional de Saúde do Escolar). 2019</p>
C435		<p><b>Does your country have any plans to repeat any of the above or to undertake a new tobacco survey within three to five years of your last survey? Please provide details in the space below.</b></p> <p>- The Surveillance System for Risk and Protective Factors for Chronic Illness (VIGITEL) is a annual survey. - The Global Adult Tobacco Survey will be repeated in five years. - The Global Youth Survey will be repeated in three years.</p>
1		<b>regional and global exchange of publicly available national:</b>
	1	<p><b>scientific, technical, socioeconomic, commercial and legal information?</b></p> <p>Yes</p>
	2	<p><b>information on the practices of the tobacco industry?</b></p> <p>Yes</p>
	3	<p><b>information on the cultivation of tobacco?</b></p> <p>Yes</p>
1		<b>an updated database of:</b>
	1	<p><b>laws and regulations on tobacco control?</b></p> <p>Yes</p>
	2	<p><b>information about the enforcement of laws on tobacco control?</b></p> <p>Yes</p>
	3	<p><b>pertinent jurisprudence?</b></p> <p>Yes</p>
C438		<b>Please provide a brief description of the progress made in implementing Article 20 (Research, surveillance and exchange of information) in the past two years or since submission of your last report.</b>
C439		<b>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether you included information on WHO FCTC implementation in your Voluntary National Review (VNR) on the Sustainable Development Goals (SDGs),</b>

		<b>related to target 3.a).</b> XXX
--	--	---------------------------------------

**D. INTERNATIONAL COOPERATION AND ASSISTANCE**

D0		<b>Pursuant to Article 21.1(c) and in accordance with Article 26, have you either provided or received financial or technical assistance (be it through unilateral, bilateral, regional, subregional or other multilateral channels, including relevant regional and international intergovernmental or nongovernmental organizations and financial and development institutions) for the development and strengthening of multisectoral, comprehensive tobacco control programmes of developing country Parties and Parties with economies in transition in any of the following areas:</b>
1		<b>development, transfer and acquisition of technology, knowledge, skills, capacity and expertise related to tobacco control?</b>
	1	<b>Assistance provided</b> Yes
	2	<b>Assistance received</b> Yes
1		<b>provision of technical, scientific, legal and other expertise to establish and strengthen national tobacco control strategies, plans and programmes?</b>
	1	<b>Assistance provided</b> Yes
	2	<b>Assistance received</b> Yes
1		<b>appropriate training or sensitization programmes for appropriate personnel in accordance with Article 12?</b>
	1	<b>Assistance provided</b> No
	2	<b>Assistance received</b> Yes
1		<b>provision of the necessary material, equipment and supplies, as well as logistic support, for tobacco control strategies, plans and programmes?</b>
	1	<b>Assistance provided</b> Yes
	2	<b>Assistance received</b> No
1		<b>identification of methods for tobacco control, including comprehensive treatment of nicotine addiction?</b>
	1	<b>Assistance provided</b> No
	2	<b>Assistance received</b>

		No
1		<b>promotion of research to increase the affordability of comprehensive treatment of nicotine addiction?</b>
	1	<b>Assistance provided</b> No
	2	<b>Assistance received</b> No
D7		<b>Please identify the Party or Parties from which assistance was received or to which assistance was provided.</b>  Cabo verde, Colombia and Paraguay
D8		<b>Please provide information about any assistance provided or received in the space below, including any support received from nongovernmental organizations (please, specify).</b>  - National Cancer Institute - was redesignated as a Collaborating Center of the Pan American Health Organization / WHO on Tobacco Control.
D9		<b>If you have not received or provided assistance in any of the aforementioned areas, please identify any financial or technical assistance that may be under consideration, if appropriate.</b>  No.
D10		<b>Have you encouraged relevant regional and international intergovernmental organizations and financial and development institutions in which you are represented to provide financial assistance for developing country Parties and for Parties with economies in transition to assist them in meeting their obligations under the Convention?</b>  No
D11		<b>Please provide details in the space below.</b>

**E. PRIORITIES AND COMMENTS**

E1		<p><b>What are the priorities for implementation of the WHO Framework Convention on Tobacco Control in your jurisdiction?</b></p> <p>- Establish a tax-based mechanism to fund tobacco control policies and to compensate public health costs from tobacco consumption. - Support and monitor legislative proposals requiring cigarette plain packaging. - Expansion of the commitment between bordering countries. - Implement new health warnings on cigarette packaging. - Strengthen the legislation regarding the exhibition of cigarette packages at POS.</p>
E2		<p><b>Have you identified any specific gaps between the resources available and the needs assessed for implementing the WHO Framework Convention on Tobacco Control?</b></p> <p>Yes</p>
E3		<p><b>Please provide details in the space below.</b></p> <p>Limited financial resources to maintain regular advocacy, campaigns, regional support to states and municipalities and to strengthen current policies.</p>
E4		<p><b>What, if any, are the constraints or barriers, other than lack of resources, you have encountered in implementing the Convention?</b></p> <p>- Tobacco industry lobby in all sectors. (e.g.: National Congress, Executive). - Tobacco industry lawsuits against tobacco control measures. - Lack of knowledge by legislators and judges on the damages of smoking to public health actions</p>
1		<p><b>Do you have any of the following products available on your national tobacco market?</b></p>
	1	<p><b>smokeless tobacco products</b></p> <p>Yes</p>
	2	<p><b>water pipe tobacco</b></p> <p>Yes</p>
	3	<p><b>Electronic Nicotine Delivery Systems (ENDS)</b></p> <p>Yes</p>
	4	<p><b>Electronic Non-Nicotine Delivery Systems (ENNDS)</b></p> <p>No</p>
	5	<p><b>heated tobacco products (HTPs)</b></p> <p>No</p>
1		<p><b>Have you adopted and implemented any policy or regulation that is specific to the following tobacco products?</b></p>
	1	<p><b>smokeless tobacco products</b></p> <p>Yes</p>
	2	<p><b>water pipe tobacco</b></p> <p>Yes</p>
	3	<p><b>Electronic Nicotine Delivery Systems (ENDS)</b></p> <p>Yes</p>
	4	<p><b>Electronic Non-Nicotine Delivery Systems (ENNDS)</b></p> <p>No</p>



	5	<b>heated tobacco products (HTPs)</b> No
E7		<b>If you have any relevant information related to questions E5 and E6, please provide details in the space below.</b>  - National campaign about the harms of water pipe tobacco - ANVISA's resolution prohibits to sell, import and advertise ENDS nationwide - Regulation of smokeless tobacco packages
E8		<b>Do you have a costed national tobacco control plan or strategy?</b> No
E81		<b>If you answered "Yes" to question E8, is this costed national tobacco control plan or strategy fully funded?</b>  N/A
E82		<b>Please attach the costed plan or strategy here.</b>
E9		<b>Please provide the government's expenditure on tobacco control, for the latest year available, in your country's currency.</b>  xxx
E10		<b>Have you adopted and implemented any national legislative, executive, administrative and/or other measures that go beyond the requirements of the Convention in line with Article 2.1 (e.g, endgame strategies, smoke-free generations, tobacco free villages or cities)?</b>  No
E101		<b>If you answered "Yes" to question E10, please provide details.</b>
E11		<b>Please attach any documentation relevant to any sections of the reporting instrument.</b>
E12		<b>Please provide any other relevant information not covered elsewhere that you consider important.</b>
E13		<b>Your suggestions for further development and revision of the reporting instrument:</b>